Linike Medical Group

LNMG

Specialty Retail · Consumer Cyclical

Price

$0.01

-0.00 (-6.03%)

Market Cap

$3.5M

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Apr 30, 2026

How the score breaks down

Quality

Weak

Growth

Mixed

Cash Flow

Data not available

Stability

Mixed

Valuation

Good

Track this stock — start free trial

Share count rising — dilution

+31.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 509.5M (2021) → 668.9M (2025)

Winston Score History

The full picture

Linike Medical Group Ltd (ticker: LNMG) does not appear in widely available public financial databases, and there is very little verifiable information about its operations, products, or customers. The company is classified under Shell Companies within the Financial Services sector, which means it may be a holding company, a blank-check entity, or a vehicle in the process of acquiring or merging with an operating business. Without confirmed details, describing its core products or end markets with accuracy is not possible.

The company carries a market cap near zero, suggesting it is extremely small or thinly traded. Its gross margin of 58.2% and operating margin of 16.5% hint that some revenue-generating activity may exist, but the very low ROIC of 1.1% indicates capital is not being used efficiently. Shell companies in this classification carry significant risks for investors, including limited transparency, sparse regulatory filings, and uncertainty about what the underlying business actually is or will become.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

YoY Growth Rate

EPS data limited

R&D Spend

$0/ year

0.0% of revenue

Below sector average (4%)

Research and development spending

Insider Activity

83.1%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~0 months

$41,526 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Linike Medical Group has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

0.0%

Thin — 0.0% gross margin

Profit after running costs

Operating Margin

9.9%

Modest — 9.9% operating margin

Return on the money invested

ROCE

0.5%

Weak — 0.5% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

Data not available

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.43

Conservative — low debt load (0.43)

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

3.8x

Attractive valuation — P/E 3.8

P/E under 10. The price tag is small relative to last year's profit.

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial